Influenza vaccination in patients with juvenile idiopathic arthritis under different treatments: safety and immune response

Table 2 Basic laboratory findings

	JIA patients treated with MTX	JIA patients treated with MTX/ADA	Healthy controls	Significance (p-value)
	JIA patients treated with MTX	JIA patients treated with MTX/ADA	Healthy controls	p1	p2	p3
ESR (mm/hour)	12.00 ± 7.82	10.85 ± 6.63	8.68 ± 5.88	0.295	0.509	0.851
CRP (mg/l)	0.85 ± 1.67	1.03 ± 2.13	1.09 ± 1.68	0.923	0.992	0.957
Leukocyte (abs.)	6920 ± 2380	7220 ± 1470	6770 ± 1350	0.959	0.630	0.846
ANC (G/l)	3.94 ± 1.57	3.71 ± 1.03	3.69 ± 1.14	0.803	0.999	0.814
Monocyte (%)	0.33 ± 0.18	0.38 ± 0.12	0.33 ± 0.84	0.988	0.429	0.392
Thrombocyte (G/l)	304.06 ± 62.47	295.04 ± 58.78	302.05 ± 89.23	0.996	0.939	0.917

(p1 = MTX and control, p2 = MTX/ADA and control, p3 = MTX and MTX/ADA, ANC: absolute neutrophil count)

ISSN: 1546-0096